Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 1/2019

01-02-2019 | Original Article

Frequency of Behçet’s disease among a group of visually impaired adults

Authors: Oguz Abdullah Uyaroglu, Emrah Seyhoglu, Abdulsamet Erden, Cevanşir Vahabov, Hakan Babaoglu, Berkan Armagan, Alper Sari, Levent Kilic, Olcay Tatar, Sule Apras Bilgen, Omer Karadag, Umut Kalyoncu

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2019

Login to get access

Abstract

Background

Behçet’s disease (BD) is one of the reasons of acquired visual impairment among young adults. Ocular involvement is a significant cause of disability in BD. The objective of this study is to assess the prevalence of BD among a group of adults who has visual impairment.

Methods

Ankara Metropolitan Municipality Education and Technology Center is one of the official institutions which records and follows the demographic data of visually impaired people in Turkey. In November 2014, there were 675 visually impaired people recorded at this center. Medical history was taken from 294 adults by phone in November and December of 2014. Participants were asked if the visual impairment had been either acquired or congenital. If the patients had BD or suspicious BD, they were recalled for detailed investigation which would be carried out by an internist, a rheumatologist and an ophthalmologist.

Results

Two hundred thirteen of 294 (72.4%) visually impaired adults were male. One hundred nine of 294 (37.1%) had acquired visual impairment. Six (5.5%) of those 109 patients had BD. Overall prevalence of BD among study group was 2.04%.The median age of people with BD was 35 years. The median age at BD diagnosis was 16.5 years and the median duration from diagnosis to visual loss was 2.5 years.

Conclusion

BD is still one of the causes of acquired visual impairment in Turkey. In this study, BD prevalence among a visually impaired adult group was 2.04%. BD accounted for 5.5% among adults who had acquired visual impairment. In a study of 1965, BD prevalence among people with acquired blindness was 12%. However, this study was conducted at pre-immunosuppressive period. Our prevalence is obviously lower than those studies. Extended population-based studies are needed for population estimations.
Literature
1.
go back to reference Krumpaszky H, Dietz K, Mickler A, Selbmann H (1999) Mortality in blind subjects. Ophthalmologica 213:48–53CrossRefPubMed Krumpaszky H, Dietz K, Mickler A, Selbmann H (1999) Mortality in blind subjects. Ophthalmologica 213:48–53CrossRefPubMed
2.
go back to reference Pascolini D, Mariotti SP (2012) Global estimates of visual impairment: 2010. Br J Ophthalmol 96:614–618CrossRefPubMed Pascolini D, Mariotti SP (2012) Global estimates of visual impairment: 2010. Br J Ophthalmol 96:614–618CrossRefPubMed
4.
go back to reference Ozyazgan Y, Ucar D, Hatemi G, Yazici Y (2015) Ocular involvement of Behçet’s syndrome:a comprehensive review. Clin Rev Allergy Immunol 49:298–306CrossRefPubMed Ozyazgan Y, Ucar D, Hatemi G, Yazici Y (2015) Ocular involvement of Behçet’s syndrome:a comprehensive review. Clin Rev Allergy Immunol 49:298–306CrossRefPubMed
5.
go back to reference Mochizuki M, Akduman L, Nussenblatt RB (1996) Behcet’s disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity. Mosby, St. Lois, pp 663–675 Mochizuki M, Akduman L, Nussenblatt RB (1996) Behcet’s disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity. Mosby, St. Lois, pp 663–675
6.
go back to reference Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain A, Gul A, Houman MH, Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N, Yurdakul S, Yazici H, EULAR Expert Committee (2008) EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67:1656–1662CrossRefPubMed Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain A, Gul A, Houman MH, Kötter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stübiger N, Yurdakul S, Yazici H, EULAR Expert Committee (2008) EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67:1656–1662CrossRefPubMed
7.
go back to reference Davatchi F, Assaad-Khalil S, Calamia K, Crook J, Sadeghi-Abdollahi B, Schirmer M et al (2014) The international criteria for Behçet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347CrossRef Davatchi F, Assaad-Khalil S, Calamia K, Crook J, Sadeghi-Abdollahi B, Schirmer M et al (2014) The international criteria for Behçet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347CrossRef
8.
9.
go back to reference Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H (2007) Ocular features of Behçet’s disease: an international collaborative study. Br J Ophthalmol 91:1579–1582CrossRefPubMedPubMedCentral Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H (2007) Ocular features of Behçet’s disease: an international collaborative study. Br J Ophthalmol 91:1579–1582CrossRefPubMedPubMedCentral
10.
go back to reference Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas HH, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas HH, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380CrossRefPubMed
13.
go back to reference Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42:346–351CrossRefPubMed Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42:346–351CrossRefPubMed
14.
go back to reference Shimizu T, Tanaka I, Ogino K (1970) Current status of Behpet’s disease in Japan. Igaku no Ayumt 75:332–341 Shimizu T, Tanaka I, Ogino K (1970) Current status of Behpet’s disease in Japan. Igaku no Ayumt 75:332–341
Metadata
Title
Frequency of Behçet’s disease among a group of visually impaired adults
Authors
Oguz Abdullah Uyaroglu
Emrah Seyhoglu
Abdulsamet Erden
Cevanşir Vahabov
Hakan Babaoglu
Berkan Armagan
Alper Sari
Levent Kilic
Olcay Tatar
Sule Apras Bilgen
Omer Karadag
Umut Kalyoncu
Publication date
01-02-2019
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 1/2019
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-018-1783-4

Other articles of this Issue 1/2019

Irish Journal of Medical Science (1971 -) 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine